Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Conditions
- Advanced Esophageal Adenocarcinoma
- Advanced Gastric Adenocarcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Clinical Stage III Gastric Cancer AJCC v8
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IV Gastric Cancer AJCC v8
- Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Metastatic Esophageal Adenocarcinoma
- Metastatic Gastric Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Unresectable Esophageal Adenocarcinoma
- Unresectable Gastric Adenocarcinoma
- Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Computed Tomography
- PROCEDURE: Magnetic Resonance Imaging
- BIOLOGICAL: Nivolumab
- DRUG: Paclitaxel
- OTHER: Questionnaire Administration
- BIOLOGICAL: Ramucirumab
Sponsor
National Cancer Institute (NCI)